Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Y Konopleva

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Best Practice & Research. Clinical Haematology|March 25, 2021
Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclaxMarina Y Konopleva
Cancer Journal (Sudbury, Mass.)|January 24, 2022
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid LeukemiaAbhishek Maiti, Marina Y Konopleva
Cancer Cell|March 14, 2018
ORY-1001: Overcoming the Differentiation Block in AMLPrithviraj Bose, Marina Y Konopleva
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Leukemia stem cells and microenvironment: biology and therapeutic targetingMarina Y Konopleva, Craig T Jordan
Cancer Drug Resistance (Alhambra, Calif.)|July 8, 2022
Venetoclax resistance: mechanistic insights and future strategiesFaustine Ong, Kunhwa Kim, Marina Y Konopleva
Clinical Lymphoma, Myeloma & Leukemia|April 30, 2022
Beyond BCL-2 Inhibition in Acute Myloid Leukemia: Other Approaches to Leverage the Apoptotic PathwayAbhishek Maiti, Bing Z Carter, Michael Andreeff, et al.
Blood Advances|December 24, 2019
Venetoclax for AML: changing the treatment paradigmDaniel A Pollyea, Maria Amaya, Paolo Strati, et al.
Blood|July 24, 2015
PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 miceXiaodong Cheng, Michael Byrne, Kevin D Brown, et al.
Cell Death Discovery|March 27, 2025
BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanismKapil Saxena, Shao-Hsi Hung, Esther Ryu, et al.
Blood Advances|May 5, 2022
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemiaChong Chyn Chua, Danielle Hammond, Andrew Kent, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Best Practice & Research. Clinical Haematology|March 25, 2021
Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclaxMarina Y Konopleva
Cancer Journal (Sudbury, Mass.)|January 24, 2022
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid LeukemiaAbhishek Maiti, Marina Y Konopleva
Cancer Cell|March 14, 2018
ORY-1001: Overcoming the Differentiation Block in AMLPrithviraj Bose, Marina Y Konopleva
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Leukemia stem cells and microenvironment: biology and therapeutic targetingMarina Y Konopleva, Craig T Jordan
Cancer Drug Resistance (Alhambra, Calif.)|July 8, 2022
Venetoclax resistance: mechanistic insights and future strategiesFaustine Ong, Kunhwa Kim, Marina Y Konopleva
Clinical Lymphoma, Myeloma & Leukemia|April 30, 2022
Beyond BCL-2 Inhibition in Acute Myloid Leukemia: Other Approaches to Leverage the Apoptotic PathwayAbhishek Maiti, Bing Z Carter, Michael Andreeff, et al.
Blood Advances|December 24, 2019
Venetoclax for AML: changing the treatment paradigmDaniel A Pollyea, Maria Amaya, Paolo Strati, et al.
Blood|July 24, 2015
PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 miceXiaodong Cheng, Michael Byrne, Kevin D Brown, et al.
Cell Death Discovery|March 27, 2025
BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanismKapil Saxena, Shao-Hsi Hung, Esther Ryu, et al.
Blood Advances|May 5, 2022
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemiaChong Chyn Chua, Danielle Hammond, Andrew Kent, et al.
Pageof 7